Bristol Myers Squibb (CELG-RI) Gross Margin Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Gross Margin Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 32.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 292.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -396.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -391.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 71.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 484.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 96.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -144.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 16.00 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -124.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -124.00 |
| Mar 31, 2026 | -270.00 |
| Dec 31, 2025 | 622.00 |
| Sep 30, 2025 | -324.00 |
| Jun 30, 2025 | -71.00 |
| Mar 31, 2025 | -237.00 |
| Dec 31, 2024 | -1,507.00 |
| Sep 30, 2024 | -201.00 |
| Jun 30, 2024 | -116.00 |
| Mar 31, 2024 | -208.00 |
| Dec 31, 2023 | -118.00 |
| Sep 30, 2023 | -188.00 |
| Jun 30, 2023 | -274.00 |
| Mar 31, 2023 | -142.00 |
| Dec 31, 2022 | -308.00 |
| Sep 30, 2022 | -127.00 |
| Jun 30, 2022 | -193.00 |
| Mar 31, 2022 | 444.00 |
| Dec 31, 2021 | 663.00 |
| Sep 30, 2021 | 403.00 |